ALK
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB11260 | TPX-0005 | 1802220-02-5 | TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively. |
| FB12139 | TP0427736 HCl | 2459963-17-6 | TP0427736 HCl is the HCl form of TP0427736 which is an inhibitor of ALK5 with IC50 of 2.72 nM and can reduce TGF-β induced growth. |
| FB12090 | SM 16 | 614749-78-9 | SM 16 is an an ATP-competitive ALK5/ALK4 inhibitor with IC50 value between 160 and 620 nM for inhibition of TGF-β1-induced Smad2/3 phosphorylation in cell study. |
| FB08690 | Lorlatinib | 1454846-35-5 | PF-06463922 is an orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of < 0.02 nM, < 0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. |
| FB05359 | NVP-TAE 684 | 761439-42-3 | NVP-TAE684 is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. |
| FB00605 | LDK378 2HCl | 1380575-43-8 | LDK378 2HCl is a selective ALK inhibitor with an IC50 of 0.2 nM, and also inhibits InsR, IGF-1R, STK22D, FLT3 and FGFR2 with IC50 values of 7 nM, 8 nM, 23 nM, 60 nM and 260 nM. |
| FB11735 | JH-VIII-157-02 | 1639422-97-1 | JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. |
| FB02794 | HG-14-10-04 | 1356962-34-9 | HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM. |
| FB02263 | Entrectinib | 1108743-60-7 | Entrectinib is an oral pan-Trk, ROS1, and ALK inhibitor, with IC50 of 1.7/0.1/0.1 nM, 0.2 nM, and 1.6 nM for Trk A/B/C, ROS1, and ALK, respectively. |
| FB02576 | X-376 | 1365267-27-1 | Ensartinib is a potent inhibitor ofALK, which is used to treat non-small-cell lung cancer. |
| FB12120 | Ensartinib | 1370651-20-9 | Ensartinib is a novel, potent anaplastic lymphoma kinase (ALK) small molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1 and SLK. ALK autophosphorylation is significantly diminished by X-396, albeit at higher concentrations required to block autophosphorylation of the wild-type fusion. |
| FB02113 | Crizotinib | 877399-52-5 | Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley. |
| FB00249 | Crizotinib HCl | 1415560-69-8 | Crizotinib HCl is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley. |
| FB08345 | CH5424802 HCl | 1256589-74-8 | CH5424802 HCl is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
| FB08112 | Ceritinib | 1032900-25-6 | Ceritinib is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. |
| FB10146 | CEP-28122 Mesylate | 1431697-88-9 | CEP-28122 mesylate is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay. |
| FB01527 | CEP-28122 | 1022958-60-6 | CEP-28122 is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay. |
| FB02340 | Brigatinib | 1197953-54-0 | Brigatinib is a selective ALK inhibitor with IC50 value of 0.37nM, and also inhibits ROS1, FLT3, FLT3-D835Y mutant and EGFR less potently. |
| FB12118 | Belizatinib | 1357920-84-3 | Belizatinib is a selective ALK inhibitor with IC50 value of 0.7nM, as well as shows potency against TRK A, B, and C with IC50 values<3nM. |
| FB08677 | AZD3463 | 1356962-20-3 | AZD3463 is an orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. |
| FB00489 | ASP3026 | 1097917-15-1 | ASP3026 is a selective inhibitor for ALK with IC50 of 3.5 nM. |
| FB01217 | ALK-IN-1 | 1197958-12-5 | AP26113 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR. |
| FB10851 | ALK Inhibitor C29 | 2093414-37-8 | ALK inhibitor C29 shows promising anti-ALK activities in enzymatic- and cell-based assays, while in vivo H3122 xenograft model study showed that it effectively suppressed ALK-driven tumor growth. |
| FB06278 | ALK Inhibitor 2 | 761438-38-4 | ALK inhibitor 2 is a selective inhibitor for the ALK kinase. |
| FB06277 | ALK Inhibitor 1 | 761436-81-1 | ALK inhibitor 1 is a selective inhibitor for the ALK kinase. |
| FB07242 | Alectinib | 1256580-46-7 | Alectinib is a potent ALK inhibitor with IC50 of 1.9 nM while also inhibits F1174L, R1275Q, and L1196M mutants of ALK (IC50s = 1.0, 3.5, and 1.6 nM, respectively). |